CD4 masking during human immunodeficiency virus type 1 infection, quantified on peripheral blood lymphocytes, is a potential marker of disease progression.
In human immunodeficiency virus type 1 (HIV-1)-infected adults, the proportion of gp120-free CD4 molecules on the surface of T lymphocytes was measured by double-epitope EIA and expressed as a CD epitope concentration ratio. In 51% of these patients (n=81), CD4 T cells showed a significant decrease (up to 100%) in the accessibility of the CD4 epitope in the D1 domain remained accessible. Of interest, a significant increase in the CD4 gp120 binding site concentration, without a change in T cell counts, was observed within 10 days after initiation of zidovudine treatment. Furthermore, CD4 masking by gp120 was associated with a poor clinical patient status. The assessment of the CD4 epitope concentration ratio is proposed as a surrogate marker of disease progression in HIV-1-infected patients.
Carrière
D
D
Sanofi Recherche (Laboratoire d'Immunologie), Montpellier, France.
Vendrell
J
J
Berthier
A
A
Atoui
N
N
Salhi
S L
SL
Reynes
J
J
Gros
P
P
Fontaine
C
C
Jansen
A
A
Huguet
M
M
Ait-Cheik
L
L
Pau
B
B
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D015415:Biomarkers; D015704:CD4 Antigens / Q000378:metabolism*; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000821:virology; D002462:Cell Membrane / Q000276:immunology / Q000821:virology; D016655:HIV Core Protein p24 / Q000097:blood; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D015497:HIV-1; D006801:Humans; D013601:T-Lymphocytes / Q000276:immunology* / Q000821:virology; D015215:Zidovudine / Q000627:therapeutic use
D000998:Antiviral Agents; D015415:Biomarkers; D015704:CD4 Antigens; D016655:HIV Core Protein p24; D015699:HIV Envelope Protein gp120; D015215:Zidovudine